Accentus Medical, a leading UK medical technology company that supplies advanced coatings and surface treatments to the medical device industry, announced today that it has successfully completed the installation and initial demonstration of a prototype manufacturing plant for its Agluna® anti-infective technology, following the award of a grant worth £330,000 from the Technology Strategy Board within the High Value Manufacturing call.
Accentus Medical was awarded the grant in December 2009 in collaboration with Stanmore Implants Worldwide, an existing licensee and customer of Agluna® in the field of custom made limb salvage devices and patient specific joint replacements, and academic partner University College London. Following the successful development and clinical proof of concept of Agluna®, the principal objective of the grant project was to demonstrate commercial scale manufacture of the Agluna® technology.
Philip Agg, Chief Executive of Accentus Medical, said: “The Technology Strategy Board grant has been crucial in demonstrating our ability to manufacture the Agluna® technology on a commercial scale. This capability will add to the company’s established manufacturing capability in supplying to global orthopaedic device customers its Acusure® range of plasma spray coatings for implant fixation.
“We now look forward to collaborating with Stanmore Implants Worldwide in securing regulatory approval for products treated with the Agluna® technology. The ability to demonstrate to commercial partners that we are able to meet the demand for commercial manufacturing represents a significant development for Accentus, enabling the company to compete on a global scale in the medical technology sector.”
Robin Wilson, Lead Technologist for High Value Manufacturing at Technology Strategy Board, said: “We are very pleased to see Accentus Medical benefiting from our financial support in developing a commercial scale manufacturing capability for the innovative Agluna® technology. We look forward to the future economic contribution that should result from the growth of this UK-based company operating in the high-value medical technology sector.”
-ends-
For further information, please contact:
Philip Agg, CEO
T: +44 (0)1235 434328
Email: enquiries@accentus-medical.com
Technology Strategy Board is now called Innovate UK